StockData

GRI Bio vs Nkarta

GRI and NKTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GRI and NKTX compare

Nkarta is the larger company, worth 30 times as much as GRI Bio ($89.5M against $3.0M).

Nkarta scores higher on the StockData Score (7 against 6 for GRI Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGRINKTX
Size and price
Market cap$3.0M$89.5M
Share price$1.35$1.25
Change, 1 year−97.1%−33.2%
Change, 5 years−100%−92.3%
Beta (5Y)1.183.10
Employees4108
StockData Score
Total score67 (better)
Valuation score11
Growth score00
Performance score01 (better)
Health score55
Dividend score00
Valuation
P/B0.3× (better)0.4×
FCF yield–−105%
Profitability
Return on equity−142%−38.8% (better)
Return on invested capital–−157%
Financial health
Debt / equity0.000.00
Current ratio10.30 (better)7.98
Altman Z-score−6.93−3.08 (better)
Piotroski F-score33
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Shareholder yield0.00%0.00%
Ownership
Held by institutions4.3%82.9%
Held by insiders26.2%35.8%
Insider net buying, 12 months–−$70.4K
Short interest, % of float4.1%8.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.